Date:…………………….. Name…………………………………………………………. Dispensing, payment per prescription Levonorgestrel is a substance which is shifted from group OTC with restriction to group OTC in CZE. Even though there are important information you have to explain to patient. Open in Moodle - files: Levonorgestrel 1, Levonorgestrel 2 Task 1: What’s Levonorgestrel used for? Task 2: Is there mentioned any age limit for use? Task 3: How often can the patient use levonorgestrel? (Escapelle pill) Task 4: In which situtation is better to contact the doctor before using levonorgestrel? In CZE medicinal product ELLAONE was directly classified as OTC product. Compare this product with products containing Levonorgestrel (different active substance and time limit for use) (use file in Moodle ELLAONE) Ellaone contains active substance…………………. can be used within …. hours (…. days) of contraceptive failure. Medicinal products – OTC with restricted dispensing: Task 5: Medicnal products with Pseudoephedrine The total amount of pseudoephedrine for an individual dispensing shall not exceed 900 mg pseudoephedrine Is it possible to dispensed: Two packages of Modafen containing 24 tablets for one patient at the same time? Note: MODAFEN: COMPOSITION - Each tablet contains: Ibuprofenum 200 mg, Pseudoephedrini hydrochloridum 30 mg YES - NO Why? Prescription only Medicinal products with restricted dispensing Task 6: Open link http://www.sakl.cz/en/: Menu Patients a) Is there mentioned any limit for prescribing? ……………g/ month b) Describe briefly side effects of medical cannabis: c) Describe briefly inhalation using a vaporiser: Task 7 Medical Canabis can be prescribed only for bellow mentioned diagnosis. Open link in Moodle: International Statistical Classification of Diseases and Related Health Problems 10th Revision (http://apps.who.int/classifications/icd10/browse/2016/en) And write names of the diagnosis R52.1…………………………………………………………………………………………… F95.2……………………………………………………………………………………………. T09.3…………………………………. associated with R25.2…………………………………………. S14.1…………………………………………. S24.1…………………………………………. S34.1…………………………………………. G35…………………………………………. R11 …………………………………… associated with groups C00 till 97……………………………….. B20 till 24 ……………………………… As was explained in the lecture: In the Czech Republic there is statutory pricing for all reimbursable pharmaceuticals. Prices of non‐reimbursable pharmaceuticals are not regulated. Task 8 In accordance to above mentioned rule - Is there the price regulation? Aclasta 5mg INF SOL 100ml human medicnal product with marketing authorisation with reimbursement: YES - NO Cilkanol POR CPS DUR 30X300MG human medicnal product with marketing authorisation, OTC, without reimbursement: YES - NO Stilnox por.tbl.flm.20x10mg human medicnal product with marketing authorisation, Prescription only medicinal product, without reimbursement: YES – NO Meloxivet – authorised medicinal produc, Prescription only medicinal product, veterinary use YES - NO ______________________________________________________________________________ SIDC – List of reibursed medicinal products Task 9: Open file in Moodle: List of reimbursed medicinal products Find product: ABRAXANE 5 MG/ML : Maximum reimbursement is: Specialisation: Increased maximum reimbursement: Task 10: Open file List of reimbursed medicinal products Is there mentioned medicinal product with brand name „OSTEOGENON“? No – and it means it is not reimbursed medicinal product No – and it means it is fully reimbursed Yes and reimbursement is…………………… Medicinal product: Payment per prescription Co-payment = Pharmacy retail price - Reimbursement Rp. EGILOK 100 MG POR TBL NOB 60X100MG Exp. Orig. No I (unam) D.S. 2x1 Egilok 100 mg 60 tbl / 1 package: Rough price for the final consumer:153,85 Maximum reimbursement from health insurance:79,85 Co-Payment: 153,85 - 79,85 = 74 CZK/1 box; Total: 74 CZK Patient x Insurance: 79,85 CZK Task 11: Prescription: Rp. Yaz 0.02mg/3mg por.tbl.flm.3x28 Exp. Orig. No II (duas) D.S. 1 / day Yaz 0.02mg/3mg 3x28 tbl / 1 package Rough price for the final consumer:1030 CZK Maximum reimbursement from health insurance:0 Co-Payment:………………. Total: …………….. Patient x …………..Insurance: Task 12: Rp. Lozap H por tbl flm 30 Exp. Orig. No III (tres) D.S. 1 in the morning Lozap H 30 tbl Rough price for the final consumer:111,54 Maximum reimbursement from health insurance:83,54 Co-Payment:………………. Total: …………….. Patient x …………..Insurance: ______________________________________________________________________________ Reminder: Oop 04 – 13 (Regulation by SÚKL) - reimbursement of medicinal products prepared in the pharmacy - there are written groups of medicinal products which prepared in the pharmacy and which are NOT reimbursed in accordance to their indication or content: a) combination of substances with analgetic and/or antipyretic effect, except of combination with codeine for gastroenterology; antiphlogistics, b) decongescents of nose mucose, combinations - decongescens + other substances c) medicinal products with herbal origin (tea, phytopharmacon from group No 57 mentioned in Regulation 385/2007, cannabis included) d) vitamins, combination of vitamins, combination - vitamins + minerals or other substances for p.o. use e) methionin for p.o. use except of hereditary diseases f) expectorants and antitusics g) treatment of erectile dysfunction h) products containing: - chinidin or hydrargyri amidochloridum. i) products containing combination of: - coffein and ephedrin j) antihemorrhoidalia for local application and rectal use Task 13) Rp. Chinidinii sulfurici 0,1 Papaverini chl. 0,025 Phenobarbitali 0,015 M.f.pulv D.t.d. No XX (viginti) ad caps S:3x1 Will be this medicinal product reimbursed? Yes - No Hydrogenii peroxidati 30% 4,0 Adeps lanae 6,0 Vaselini flavi ad 20,0 M.f.ung Will be this medicinal product reimbursed? Yes - No Task 14) Write your opinion: Is it better to have same prices of medicinal product in all pharmacies in the country or to have possibility of different competitive prices and discounts? Explain why. ……………………………………………………………………………………………………… ……………………………………………………………………………………………………… ……………………………………………………………………………………………………… ……………………………………………………………………………………………………… ……………………………………………………………………………………………………… ……………………………………………………………………………………………………… ……………………………………………………………………………………………………… ………………………………………………………………………………………………………